Term ends Aug 6, 2028 · High confidence
20-year base term ends Oct 4, 2032
Held by Wellhouse Pharma, LLC
Filed Oct 4, 2012 as application 13/644,283 · Granted May 24, 2016
Base term plus 65 days of patent term adjustment (USPTO delay) · capped by a resolved terminal disclaimer
Today
2012
2032
Clock starts
Oct 4, 2012
Oct 4, 2012
Term ends
Aug 6, 2028
Aug 6, 2028
Granted
May 24, 2016
May 24, 2016
base term
after the term ends
fee events
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
65
Days of term adjustment
Read from the USPTO patent term adjustment record, not recalculated here.
Capped
Terminal disclaimer
Resolved from the filed document, referencing US 8,222,292.
2 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
23
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term runs 65 days past its 20-year base term on prosecution delay. A terminal disclaimer resolved from the filed document caps it earlier. 2 of 3 maintenance fees are paid so far. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Oct 4, 2012, when this application, 13/644,283, was filed | Oct 4, 2032 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | +65 days, USPTO patent term adjustment record | Dec 8, 2032 | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 8,222,292) | capped to Aug 6, 2028 | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 2 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Aug 6, 2028 | High confidence |
This family
| US 9,345,771 | this patent Aug 2028 | Aug 2028 |
| US 11,224,660 | In force May 2035 | May 2035 |
| US 11,331,279 | In force May 2035 | May 2035 |
| US 9,662,334 | In force Nov 2034 | Nov 2034 |
| US 10,265,293 | In force Aug 2028 | Aug 2028 |
| Application 15/166,476 | Pending not computed | not computed |
| Application PCT/US2016/034565 | PCT application no patent term | no patent term |
| US 10,172,833 | In force Nov 2034 | Nov 2034 |
8 of 23 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Aug 21, 2013 Reel 31049, frame 738 | Goskonda, Venkat R.; Chavan, Ashok; Kokate, Amit; Gill, Howard | Insys Therapeutics, Inc. | Assignment of Assignor's Interest |
| Sep 11, 2014 Reel 33717, frame 445 | Goskonda, Venkat R; Kokate, Amit; Chavan, Ashok; Gill, Howard | Insys Pharma, Inc. | Corrective Assignment to Correct the Receiving Party's Data Previously Recorded at Reel: 031049 Frame: 0738. Assignor(S) Hereby Confirms the Assignment. |
| Feb 3, 2016 Reel 37652, frame 49 | Insys Pharma, Inc. | Insys Development Company, Inc. | Assignment of Assignor's Interest |
| Dec 2, 2019 Reel 51152, frame 366 | Insys Development Company, Inc.; Insys Pharma, Inc.; Insys Therapeutics, Inc. | Fresh Cut Development, LLC | Assignment of Assignor's Interest |
| Dec 2, 2019 Reel 51152, frame 396 | Fresh Cut Development, LLC | Benuvia Therapeutics Inc. | Assignment of Assignor's Interest |
| Dec 19, 2019 Reel 51381, frame 283 | Benuvia Therapeutics Inc. | Fresh Cut Development, LLC | Assignment of Assignor's Interest |
| May 6, 2021 Reel 56161, frame 408 | Fresh Cut Development, LLC | Benuvia Therapeutics, LLC | Assignment of Assignor's Interest |
| Aug 27, 2021 Reel 57649, frame 166 | Fresh Cut Development, LLC | Benuvia Therapeutics, LLC | Corrective Assignment to Correct the List of Application Numbers Previously Recorded at Reel: 055246 Frame: 0668. Assignor(S) Hereby Confirms the Assignment . |
| Dec 8, 2021 Reel 58340, frame 146 | Benuvia Therapeutics, LLC | Jupiter Wellness, Inc. | Security Interest |
| Sep 23, 2022 Reel 61190, frame 393 | Benuvia Therapeutics, LLC | Benuvia Operations, LLC | Assignment of Assignor's Interest |
| Mar 12, 2025 Reel 70482, frame 222 | Benuvia Operations, LLC | Wellhouse Pharma, LLC | Assignment of Assignor's Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
What's changing
Aug 2028
Term ends Aug 6, 2028. Maintenance fees still fall due before then
Note
The 65 days of patent term adjustment (USPTO delay) are read from the USPTO record, not recalculated by us
Disclaimer cap
This term is capped by a terminal disclaimer resolved from the filed document, referencing US 8,222,292.
Citations
77
later US patents cite this one
That is top 5% of utility patents granted in 2016 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.